title: [Complete remission in acute promyelocytic leukemia. The advantages of all-trans-retinoic acid compared to conventional chemotherapy].
abstract: In all of seven patients (six men, one woman; mean age 43 [24-55] years) with newly diagnosed acute promyelocytic leukaemia, treated between 1989 and 1993, complete remission was achieved. In three of these patients, treated between 1989 and 1991, remission was induced with conventional chemotherapy (cytarabine and anthracycline), after this in four patients with all-trans retinoic acid (tretinoin). The seventh patient who had a very rapid increase in leucocytes during tretinoin administration, was as a precaution also given conventional chemotherapy. All seven patients received consolidating chemotherapy with an intensive treatment cycle. Retrospective analysis indicated that induction with tretinoin had marked advantages: quicker regression of the clotting abnormalities (mean of 9 vs 25 days), shorter period of leukopenia (mean of 3.5 vs 30 days), shorter time until complete remission (mean of 38 vs 48 days). There were no specific side effects ascribable to tretinoin. Toxicity after chemotherapy corresponded to WHO grades 2-4. The results indicate that tretinoin markedly reduces the two main risks in the treatment of acute promyelocytic leukaemia: bleeding and infection.
authors.affiliation: III. Medizinische Klinik, Klinikum Mannheim, Universität Heidelberg.
authors.forename: E
authors.initials: E
authors.lastname: Lengfelder
authors.forename: M
authors.initials: M
authors.lastname: Simon
authors.forename: D
authors.initials: D
authors.lastname: Haase
authors.forename: F
authors.initials: F
authors.lastname: Hild
authors.forename: R
authors.initials: R
authors.lastname: Hehlmann
mesh_terms: D000328:Adult; D000616:Aminoglutethimide / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001853:Bone Marrow / Q000187:drug effects / Q000473:pathology; D003561:Cytarabine / Q000008:administration & dosage / Q000009:adverse effects; D003613:Danazol / Q000008:administration & dosage / Q000009:adverse effects; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage / Q000009:adverse effects; D011379:Prognosis; D012074:Remission Induction; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects; D013997:Time Factors; D014212:Tretinoin / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
chemical_list: D003561:Cytarabine; D013629:Tamoxifen; D000616:Aminoglutethimide; D014212:Tretinoin; D008942:Mitoxantrone; D003613:Danazol
vernacular_title: Komplette Remission bei akuter Promyelozytenleukämie. Vorteile von all-trans-Retinsäure im Vergleich mit konventioneller Chemotherapie.